Healios KK
TSE:4593

Watchlist Manager
Healios KK Logo
Healios KK
TSE:4593
Watchlist
Price: 170 JPY -0.58% Market Closed
Market Cap: 15.3B JPY
Have any thoughts about
Healios KK?
Write Note

Healios KK
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Healios KK
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Healios KK
TSE:4593
Revenue
ÂĄ549m
CAGR 3-Years
148%
CAGR 5-Years
46%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Revenue
ÂĄ22.7B
CAGR 3-Years
22%
CAGR 5-Years
27%
CAGR 10-Years
52%
PeptiDream Inc
TSE:4587
Revenue
ÂĄ47.8B
CAGR 3-Years
45%
CAGR 5-Years
47%
CAGR 10-Years
51%
Takara Bio Inc
TSE:4974
Revenue
ÂĄ44.1B
CAGR 3-Years
-10%
CAGR 5-Years
5%
CAGR 10-Years
6%
Pharma Foods International Co Ltd
TSE:2929
Revenue
ÂĄ60.6B
CAGR 3-Years
6%
CAGR 5-Years
41%
CAGR 10-Years
44%
C
Cuorips Inc
TSE:4894
Revenue
ÂĄ23.1m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Healios KK
Glance View

Market Cap
15.3B JPY
Industry
Biotechnology

Healios KK engages in the research, development, and sale of cellular and regenerative medicine. The company is headquartered in Chiyoda-Ku, Tokyo-To and currently employs 116 full-time employees. The company went IPO on 2015-06-16. is a Japan-based company mainly engaged in research and development of pharmaceutical products. The firm has compound pharmaceutical products line and induced pluripotent stem cell (iPSC) regenerative medicine product line. The compound pharmaceutical product line contains HLM0021, HLM0022 and HLM0023. The products are ophthalmological surgery adjuvants, mainly contain brilliant blue G-250 (BBG250) which help capsule temporarily safely stained to protect the inner limiting membranes and lens during surgery of vitreous and cataract. The iPSC regenerative medicine product line contains HLCR011 and HLCR012. The products are in the preclinical testing and preparation for trial in Japan, which are candidate of regenerative medicine products. The products are iPS cell derived retinal pigment epithelium (RPE) cell suspension and sheet developed in Japan, United States and Europe.

Intrinsic Value
142.38 JPY
Overvaluation 16%
Intrinsic Value
Price

See Also

What is Healios KK's Revenue?
Revenue
549m JPY

Based on the financial report for Sep 30, 2024, Healios KK's Revenue amounts to 549m JPY.

What is Healios KK's Revenue growth rate?
Revenue CAGR 5Y
46%

Over the last year, the Revenue growth was 216%. The average annual Revenue growth rates for Healios KK have been 148% over the past three years , 46% over the past five years .

Back to Top